Tempest Therapeutics Exercises Option To License Senlang’s CD7-Targeted Lentiviral Outside China
Benzinga Newsdesk 8 hours ago
FDANews
empest secures exclusive global rights outside China to a targeted lentiviral platform and portfolio of in vivo CAR-T candidates-Lead BCMA/GPRC5D dual-targeting in vivo CAR-T candidate evaluated in 13 patients with
empest secures exclusive global rights outside China to a targeted lentiviral platform and portfolio of in vivo CAR-T candidates
-Lead BCMA/GPRC5D dual-targeting in vivo CAR-T candidate evaluated in 13 patients with relapsed or refractory multiple myeloma, including patients with extramedullary disease and prior CAR-T exposure
-Encouraging preliminary clinical responses support option exercise, results planned for presentation at a major scientific conference